Novel Opioid Not Abuse-Deterrent, FDA Panel Says
May 6, 2016
Anita Gupta, DO, PharmD, an associate professor in the College of Medicine, was quoted in a May 6 MedPage Today story about an FDA advisory panel she participated in, which decided that a new drug awaiting FDA approval should not be labeled as an abuse-deterrent.
Related:
Drexel News is produced by
University Marketing and Communications.